MVM Life Science Partners — 2016 Investments
1 investments dated 2016 · listed companies and verified rows first · show all
Tarsa Therapeuticstarsatherapeutics.comFeb 2016SEC filingmedium confidence
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.
BiotechPhiladelphia, US
David Brand(Executive Officer, Director)Gregory Lumpkin(Executive Officer)
BoardRichard Kollender(Director)Martin Edwards(Director)Derek Ferguson(Director)
Board seatEric Bednarski· per SEC Form D · $2M raise · filed Feb 2016
Co-investorsForesite Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.